Dräger expands neonatal care portfolio with BiliPredics software solution

Rhea-AI Summary

Dräger has expanded its neonatal care portfolio by introducing BiliPredics, a predictive software solution developed by NeoPredics for forecasting bilirubin progression in newborns. The innovative digital application can predict bilirubin levels up to 60 hours in advance, utilizing a database of over 50,000 bilirubin measurements from nearly 10,000 newborns.

The software aims to enhance jaundice management, which affects approximately 50% of all newborns and up to 80% of premature babies. BiliPredics integrates with electronic medical records and aligns with the 2022 AAP Hyperbilirubinemia Guideline, requiring minimal clinical parameters to generate insights.

The solution complements Dräger's existing jaundice management products, including the Jaundice Meter JM-105 for non-invasive measurements and the BiliLux Phototherapy Light for treatment. This comprehensive approach supports enhanced discharge planning and data-driven decision-making in neonatal care.

Positive

• Introduction of new revenue stream through BiliPredics software solution
• Large-scale validation with 50,000+ bilirubin measurements from 10,000 newborns
• Strategic partnership with NeoPredics strengthens market position
• Integration capabilities with existing hospital EMR systems

Negative

• None.

Innovative digital application predicts bilirubin, the biomarker for neonatal jaundice, helping to enhance early intervention and care

TELFORD, Penn., March 24, 2025 /PRNewswire/ -- Dräger is expanding its neonatal care portfolio with the introduction of BiliPredics, a predictive software solution from NeoPredics designed to forecast dynamic progression of bilirubin. By leveraging a clinically validated algorithm, BiliPredics can enable healthcare professionals to anticipate bilirubin progression up to 60 hours in advance, helping to support timely and informed clinical decisions.

"Our collaboration with Dräger is a significant milestone in advancing neonatal care."

Key Benefits of BiliPredics:

• Enhanced Discharge Planning: Supports clinicians to help reduce unnecessary treatments, tests, and extended hospital stays through predictive insights into bilirubin progression.
  
  
• Data-Driven Decision Making: Utilizes an extensive database of over 50,000 individual bilirubin measurements of close to 10,000 newborns with a total of about 100,000 individual patient characteristics. 
• Integrated Jaundice Management: Helps provide a streamlined pathway for screening, monitoring, and treating neonatal jaundice.

Advanced predictive capabilities

Neonatal jaundice affects approximately 50% of all newborns and up to 80% of premature babies.¹ BiliPredics offers a proactive approach to jaundice management by forecasting bilirubin progression over 30, 48, or 60 hours. The web-based application presents this data in an accessible dashboard, helping to enable clinicians to implement preventive measures and reduce the risk of complications.

Smooth integration with clinical workflows

BiliPredics requires only a few clinical parameters to generate comprehensive insights. It aligns with established guidelines, including the 2022 AAP Hyperbilirubinemia Guideline, and can integrate with electronic medical records (EMR) to display patient data within the dashboard. The system presents bilirubin trends through comprehensible curves, helping to allow for real-time assessment and intervention.

Strategic partnership to advance neonatal care

"Through our partnership with NeoPredics, we are expanding our offering with an innovative digital solution that strengthens our position as a leader in jaundice management," said Harald Kneuer, director of neonatal care at Dräger. "By combining Dräger's market expertise with NeoPredics' advanced predictive analytics, we are providing healthcare professionals with powerful tools to improve patient outcomes while managing costs."

NeoPredics CEO, Thorsten Waloschek, echoed this sentiment: "Our collaboration with Dräger is a significant milestone in advancing neonatal care. Together, we are bridging innovative technology and clinical expertise to address critical challenges in jaundice management worldwide."

Comprehensive jaundice management solutions

Dräger's neonatal care portfolio includes solutions for both screening and treatment of neonatal jaundice. The Dräger Jaundice Meter JM-105 offers non-invasive, rapid bilirubin measurement, while the BiliLux^TM Phototherapy Light provides effective LED-based phototherapy for jaundice treatment. This approach helps ensure adherence to the latest guidelines, reinforcing the concept of "phototherapy as a drug" with precise irradiance dosing.

About Dräger

Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in 1889, Dräger generated global sales of around EUR 3.4 billion in 2023. The Lübeck-based company is represented in more than 190 countries and employs more than 16,000 people worldwide. For more information, visit www.draeger.com

NeoPredics
NeoPredics is a leader in predictive analytics and clinical decision support, with a focus on maternal and neonatal health. Committed to improving outcomes for women and children, NeoPredics develops state-of-the-art solutions like the FDA-registered and CE-certified Bilipredics jaundice management solution, addressing critical challenges in care with innovation and precision. For more information, visit www.neopredics.com

Note: The solution mentioned in this press release will not initially be available in all countries. For more information on the availability of products in your country, please visit the respective country website or contact the local Dräger sales organization.

¹Jardine LA, Woodgate P: Neonatal jaundice: phototherapy, ClinicalEvidence 2015;05:319, BMJ Publishing Group

Contact
Communications: Melanie Kamann, Tel. +49 451 882-3202, melanie.kamann@draeger.com
Press Contact North America: Laura Edwards, Tel. +1 215 565-5868, laura.edwards@draeger.com
Investor Relations: Thomas Fischler, Tel. +49 451 882-2685, thomas.fischler@draeger.com

FAQ

What is the prediction capability of Dräger's BiliPredics software for neonatal jaundice (DGWPF)?

BiliPredics can predict bilirubin progression up to 60 hours in advance, using data from over 50,000 measurements across nearly 10,000 newborns.

How does BiliPredics software integrate with existing hospital systems (DGWPF)?

The software integrates with electronic medical records (EMR), displays patient data in a dashboard, and aligns with 2022 AAP Hyperbilirubinemia Guidelines.

What percentage of newborns can benefit from Dräger's BiliPredics jaundice management system (DGWPF)?

The system can benefit approximately 50% of all newborns and up to 80% of premature babies who are affected by neonatal jaundice.

What complementary products does Dräger offer alongside BiliPredics for jaundice management (DGWPF)?

Dräger offers the Jaundice Meter JM-105 for non-invasive bilirubin measurement and BiliLux Phototherapy Light for treatment.